Email this article Clinical statistics and effectiveness of different treatments of idiopathic thrombocytopenic purpura
- Authors: Kovaleva L.G.1, Pustovaya E.I.1, Safonova T.I.1, Ryadnenko A.A.1, Kolosova E.N.1, Kovaleva LG2, Pustovaya EI2, Safonova TI2, Ryadnenko AA2, Kolosova EN2
-
Affiliations:
- Hematological Research Center, Moscow
- Issue: Vol 83, No 4 (2011)
- Pages: 60-65
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30858
- ID: 30858
Cite item
Full Text
Abstract
Material and methods. The article presents 20-year experience in observation and treatment of 1000 ITP patients gained from 1988 by the department of standardization of blood disease treatment methods on the basis of a consultative and outpatient department of Hematological Research Center. The results were assessed by conventional ITP treatment lines.
Results. First-line therapy - glucocorticoids - provided remission in 70% patients, long-term (60 months and longer) in 14%, prednisolone resistance was in 19% patients.Intravenous immunoglobulin provided a rapid hemostatic effect (in1-2 days) in all the patients. A positive response to treatment was seen in 86% patients but it was short-term (for a year and longer in 27%, resistance to the drug - 14%). Second line treatment -splenectomy - is the most effective treatment: 80% remission, 32% patients had remission for longer than 60 months. Resistance occurred in 6% patients. Ineffectiveness of treatment in 20% patients stimulated the search for new pathogenetic treatment among synthetic analogues of thrombopoietin. Clinical trials proved high efficacy of two of them - eltrombopag and romiplostim (86-87% response), possible maintenance of remission in long-term interrupted administration of low doses.
Conclusion. Modern ITP treatment allows a complete management of hemorrhagic syndrome and deep thrombocytopeny in 80% patients with provision of good quality of life and ability to work. Introduction into clinical practice of thrombopoietin analogues improves treatment results including in 20% patients resistant to all treatments in the absence of marked side effects even in long-term 3-year administration of such medication.
About the authors
Lidiya Grigor'evna Kovaleva
Elena Igorevna Pustovaya
Email: pustov@blood.ru
Tat'yana Isaakovna Safonova
Anastasiya Aleksandrovna Ryadnenko
Ekaterina Nikolaevna Kolosova
L G Kovaleva
Hematological Research Center, MoscowHematological Research Center, Moscow
E I Pustovaya
Hematological Research Center, MoscowHematological Research Center, Moscow
T I Safonova
Hematological Research Center, MoscowHematological Research Center, Moscow
A A Ryadnenko
Hematological Research Center, MoscowHematological Research Center, Moscow
E N Kolosova
Hematological Research Center, MoscowHematological Research Center, Moscow
References
- Баркаган З. С. Патология тромбоцитарного гемостаза. Тромбоцитопении. В кн.: Воробьев А. И. (ред.). Руководство по гематологии. 3-е изд. М.: Ньюдиамед; 2002; т. 3: 29-35.
- Кассирский И. А., Алексеев Г. А. Клиническая гематология. М.: Медицина; 1970.
- Климанский В. А., Алтыбаев У. А. Тромбоцитопеническая пурпура (клиника, диагностика, лечение). М.: 1984.
- Woolf S. H. Practice guidelines: a new reality in medicine. III. Impact on patient care. Arch. Intern. Med. 1996; 153: 2646- 2655.
- George J. N., Woolf S. H., Raskob G. E. et al. Idiopathic thrombocytopenic purpura. Blood 1996; 88: 3-40.
- Ковалева Л. Г., Мещерякова Л. М., Лепарский А. Е., Кошель И. В. Оценка эффективности лечения и медико-социальная адаптация взрослых больных ИТП. Гематол. и трансфузиол. 1983; 12: 17-21.
- Provan D., Stasi R., Hewlond A. et al. Interstional consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115 (2): 168-186.
- Ковалева Л. Г., Пустовая Е. И., Сафонова Т. И., Колосова Е. Н. Принципы ведения больных идиопатической тромбоцитопенической пурпурой. Пробл. гематол. 2005; 1: 54.
- Решетникова М. Е. Тактика лечения больных идиопатической тромбоцитопенической пурпурой: Автореф. дис. ... канд. мед. наук. М.; 1988.
- Мигунов В. Н., Ковалева Л. Г. Иммуноглобулины и их применение в клинической практике. В кн.: Воробьев А. И. (ред.). Очерки по производству в клинической трансфузиологии. М.: Ньюдиамед; 2006. 254-269.
- Цепа Л. С., Сандулова Ю. Ф., Отставнова Е. М. Экстренная спленэктомия у больных тромбоцитопенической пурпурой. Гематол. и трансфузиол. 1986; 31 (3): 33-36.
- Масчан А. А., Румянцев А. Г. Стимуляция продукции тромбоцитов: новый подход к лечению хронической иммунной тромбоцитопенической пурпуры. Онкогематология 2009; 1: 51-56.
- Arnold D., Nazi I., Kelton J. New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. J. Drugs 2009; 18 (6): 1-15.
- Gernsheimer T. Chronic idiopathic thrombocytopenic purpura: Mechanisms of pathogenesis. Oncologist 2009; 14 (10): 12- 21.
- Yoshika Tomiyama, Yoshitaka Miyakawa, Shinichiro Okamoto et al. Six month treatment of low dose eltrombopag is efficacious in Japanese patients with refractory chronic immune thrombocytopenic purpura (ITP). Blood 2009; 114-541.
- Garnock-Jones K. P., Keam S. J. Eltrombopag. J. Adis. Drug Profile 2009; 69 (5): 567-576.
- Bussel J. B., Cheng G., Saleh M. et al. Eltrompag for the treatment of chronic idiopathic thrombocytopenic purpura. N. Engl. J. Med. 2007; 357 (22): 2237.
- Bussel J. B., Kuter D. J., Pullarkat V., Lyons R. M. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113: 2161- 2171.
- Kute D. J., Bussel J. B., Lyons R. M. et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet 2008; 371 (96): 395-403.
Supplementary files
